Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. Trans,trans-2(4-methoxyphenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)pyrrolidine-3-carboxylic Acid
2. Zd4054
1. 186497-07-4
2. Zd4054
3. Zibotentan (zd4054)
4. Zd-4054
5. 2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-n-(3-methoxy-5-methylpyrazin-2-yl)pyridine-3-sulfonamide
6. N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
7. Zd 4054
8. Zibotentan (zd4054 )
9. N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide
10. 8054mm4902
11. C19h16n6o4s
12. Zibotentan [usan:inn:jan]
13. Unii-8054mm4902
14. Zibotentanzd4054
15. Zibotentan,zd4054
16. Zibotentan [mi]
17. Zibotentan [inn]
18. Zibotentan [jan]
19. Zibotentan [usan]
20. Zibotentan [mart.]
21. Zd4054 Form 1
22. Zibotentan [who-dd]
23. Mls006011121
24. Schembl847090
25. Zibotentan (jan/usan/inn)
26. Gtpl3539
27. Chembl1628688
28. Zibotentan, >=98% (hplc)
29. Chebi:94573
30. Dtxsid70870171
31. Hms3654h10
32. Bcp02389
33. Bdbm50532593
34. Mfcd09955343
35. S1456
36. Akos015909372
37. Ccg-264894
38. Cs-0492
39. Db06629
40. Sb17118
41. Ncgc00242479-01
42. Ncgc00242479-02
43. Ncgc00242479-03
44. Ncgc00242479-05
45. Ac-32741
46. As-57168
47. Hy-10088
48. Smr004702902
49. Ft-0768122
50. Ns00068495
51. Sw219504-1
52. D07741
53. H11009
54. L001670
55. Q198371
56. Brd-k31553034-001-01-4
57. 3-pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-
58. 3-pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-
59. N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)pridine-3-sulfonamide
60. N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2- Yl)phenyl]pyridine-3-sulfonamide
| Molecular Weight | 424.4 g/mol |
|---|---|
| Molecular Formula | C19H16N6O4S |
| XLogP3 | 1.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 6 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 141 |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 654 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in prostate cancer.
ABOUT THIS PAGE
83
PharmaCompass offers a list of Zibotentan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Zibotentan manufacturer or Zibotentan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Zibotentan manufacturer or Zibotentan supplier.
PharmaCompass also assists you with knowing the Zibotentan API Price utilized in the formulation of products. Zibotentan API Price is not always fixed or binding as the Zibotentan Price is obtained through a variety of data sources. The Zibotentan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 186497-07-4 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 186497-07-4, including repackagers and relabelers. The FDA regulates 186497-07-4 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 186497-07-4 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 186497-07-4 supplier is an individual or a company that provides 186497-07-4 active pharmaceutical ingredient (API) or 186497-07-4 finished formulations upon request. The 186497-07-4 suppliers may include 186497-07-4 API manufacturers, exporters, distributors and traders.
click here to find a list of 186497-07-4 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 186497-07-4 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 186497-07-4 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 186497-07-4 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 186497-07-4 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 186497-07-4 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 186497-07-4 suppliers with NDC on PharmaCompass.
186497-07-4 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 186497-07-4 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 186497-07-4 GMP manufacturer or 186497-07-4 GMP API supplier for your needs.
A 186497-07-4 CoA (Certificate of Analysis) is a formal document that attests to 186497-07-4's compliance with 186497-07-4 specifications and serves as a tool for batch-level quality control.
186497-07-4 CoA mostly includes findings from lab analyses of a specific batch. For each 186497-07-4 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
186497-07-4 may be tested according to a variety of international standards, such as European Pharmacopoeia (186497-07-4 EP), 186497-07-4 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (186497-07-4 USP).